KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exelixis (EXEL) EBT (2016 - 2026)

Exelixis has reported EBT over the past 17 years, most recently at $252.7 million for Q1 2026.

  • Quarterly results put EBT at $252.7 million for Q1 2026, up 36.76% from a year ago — trailing twelve months through Jan 2026 was $941.2 million (up 38.08% YoY), and the annual figure for FY2026 was $941.2 million, up 38.08%.
  • EBT for Q1 2026 was $252.7 million at Exelixis, roughly flat from $252.4 million in the prior quarter.
  • Over the last five years, EBT for EXEL hit a ceiling of $292.8 million in Q2 2024 and a floor of -$31.4 million in Q4 2022.
  • Median EBT over the past 5 years was $101.7 million (2023), compared with a mean of $132.2 million.
  • Peak annual rise in EBT hit 4329.73% in 2022, while the deepest fall reached 126.63% in 2022.
  • Exelixis' EBT stood at -$31.4 million in 2022, then soared by 427.87% to $103.0 million in 2023, then skyrocketed by 50.19% to $154.8 million in 2024, then soared by 63.1% to $252.4 million in 2025, then rose by 0.11% to $252.7 million in 2026.
  • The last three reported values for EBT were $252.7 million (Q1 2026), $252.4 million (Q4 2025), and $230.4 million (Q3 2025) per Business Quant data.